{
  "report_rows": [
    {
      "kpi": "Operating EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.90 vs. cons $2.751",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "DSA Book-to-Bill (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~1.07x vs. cons 0.993x",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$987M vs. cons $979.9M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Non-GAAP EPS (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$11.00-$11.50 mid ~$11.25 vs. cons $11.077",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Organic Revenue (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide -0.5% to -1.0% vs. cons -0.41%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "DSA H2 Organic Growth - qualitative (H2 2026)",
      "prediction": "UNCHANGED",
      "answer": "reaffirm return to growth; 3 consecutive quarters above 1.0x book-to-bill cited",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 5.0,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "FOLLOW-THROUGH \u2014 FY raise is coherent (no implicit Q3+Q4 cut); sell-side revises Q3/Q4 EPS up; short covering provides a modest bid; Investor Day in September keeps the multiple supported",
  "day5_confidence": "MEDIUM"
}